Myopia, its prevalence, current therapeutic strategy and recent developments: A Review.

Autor: Singh H; Department of Pharmaceutical Sciences, Guru Nanak Dev University; Department of Pharmacy, Government Polytechnic College, Amritsar, Punjab, India., Singh H; Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, India., Latief U; Center for Basic and Translational Research in Health Science, Guru Nanak Dev University, Amritsar, Punjab, India., Tung GK; Center for Basic and Translational Research in Health Science, Guru Nanak Dev University, Amritsar, Punjab, India., Shahtaghi NR; Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, India., Sahajpal NS; Department of Pathology, Augusta University, Georgia, USA., Kaur I; Department of Ophthalmology, Baba Farid University of Health Sciences, Faridkot, Punjab, India., Jain SK; Department of Pharmaceutical Sciences; Center for Basic and Translational Research in Health Science, Guru Nanak Dev University, Amritsar, Punjab, India.
Jazyk: angličtina
Zdroj: Indian journal of ophthalmology [Indian J Ophthalmol] 2022 Aug; Vol. 70 (8), pp. 2788-2799.
DOI: 10.4103/ijo.IJO_2415_21
Abstrakt: Myopia is a widespread and complex refractive error in which a person's ability to see distant objects clearly is impaired. Its prevalence rate is increasing worldwide, and as per WHO, it is projected to increase from 22% in 2000 to 52% by 2050. It is more prevalent in developed, industrial areas and affects individuals of all ages. There are a number of treatments available for the control of myopia, such as glasses, contact lenses, laser surgery, and pharmaceuticals agents. However, these treatments are less beneficial and have significant side effects. A novel molecule, 7-methylxanthine (7-MX), has been found to be a highly beneficial alternate in the treatment of myopia and excessive eye elongation. Many preclinical and clinical studies showed that 7-MX is effective for the treatment of myopia and is presently under phase II of clinical investigation. We have also investigated preclinical toxicity studies such as acute, sub-acute, sub-chronic, and chronic on rats. In these studies, 7-MX was found to be non-toxic as compared to other reported anti-myopic agents. Moreover, as an ideal drug, 7-MX is observed to have no or low toxicity, brain permeability, non-allergic, higher oral administration efficacy, and low treatment costs and thus qualifies for the long-term treatment of myopia. This review article on 7-MX as an alternative to myopia treatment will highlight recent findings from well-designed preclinical and clinical trials and propose a potential future therapy.
Competing Interests: None
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje